Trial Profile
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Lung-Map Sub-Study
- 07 Jun 2023 Time frame changed to date of registration to progression or treatment discontinuation, up to 2 years and 5.5 months.
- 29 Apr 2022 Status changed from active, no longer recruiting to completed.
- 12 May 2021 Planned End Date changed from 1 Apr 2022 to 20 Mar 2023.